Last reviewed · How we verify
NCT05405478
Omalizumab Efficacy in Patients With Refractory Nasal Polyps
Phase 4 trial testing Omalizumab in Nasal Polyps in 2 participants. Status unknown.
23 December 2022
Quick facts
| Lead sponsor | Shiraz University of Medical Sciences |
|---|---|
| Phase | Phase 4 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 2 |
| Start date | 1 June 2022 |
| Primary completion | 23 December 2022 |
| Estimated completion | 23 January 2023 |
| Sites | 1 location across Iran |
Drugs / interventions tested
- Omalizumab (omalizumab) — full drug profile →
- SNOT22 score
Conditions studied
- Nasal Polyps — all drugs for Nasal Polyps →
Sponsor
Shiraz University of Medical Sciences
Who can join
Adults 18 to 75, any sex, with Nasal Polyps. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
in patients with chronic rhinosinusitis with nasal polyps and concomitant asthma, they have a poor therapeutic response and a higher recurrence rate, and treatment in these patients often fails. investigators conducted this study to survey the efficacy of Omalizumab (anti IgE) on patients with refractory nasal polyp to confirm its efficacy entering to treatment guidelines.SNOT-22 score will measure at screening; on day 1; and at weeks 4, 8, 16, and 24 (point range, 0-110, with lower scores indicating better disease control and quality of life .
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05405478
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Omalizumab
Trials testing the same drug.
- NCT07356713 — A Study to Find a Suitable Dose of Exl-111 for Further Research · Phase 1 · recruiting
- NCT06934200 — Omalizumab for the Treatment of Food Allergy in Patients With Elevated Total IgE Levels · Phase 2 · recruiting
- NCT07342803 — Efficacy, Safety, and Pharmacokinetics of LP-003 Injection in Allergic Asthma Patients · Phase 2 · recruiting
- NCT06509334 — Trial of JYB1904 in Chronic Spontaneous Urticaria. · Phase 2 · recruiting
- NCT06438757 — Trial of JYB1904 in Patients With Allergic Asthma · Phase 2 · active not recruiting
Other recruiting trials for Nasal Polyps
Currently open trials in the same condition.
- NCT07245329 — Effect of Full-House ESS With Nasopharyngeal Lymphoid Tissue Ablation on Nasal Polyps · NA · recruiting
- NCT07268313 — Complete Remission After Treatment With Biologics for Nasal Polyps · Phase 4 · recruiting
- NCT05575037 — Mechanisms of Benefit of IL4RA Inhibition in Aspirin-Exacerbated Respiratory Disease · Phase 2 · active not recruiting
- NCT05094570 — Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP · Phase 4 · recruiting
- NCT05287841 — Does Batten Grafting Improve Nasal Outcomes in Septoplasty and Turbinate Reduction? · NA · recruiting
Other Shiraz University of Medical Sciences trials
Trials by the same sponsor.
- NCT07254221 — Rosuvastatin for Prevention of Anthracycline-induced Cardiac Dysfunction in Breast Cancer Patients · Phase 4 · not yet recruiting
- NCT06509893 — Ticagrelore Alone Post PCI · Phase 4 · recruiting
- NCT05876819 — Quality of Care and Welfare Services for Disabled Middle Older Adults in Iran Lebanon · enrolling by invitation
- NCT06979427 — CTFFR and Prediction of Non-Significant CAD Lesions · NA · recruiting
- NCT05711004 — Efficacy of Education Via Phone-based Text Messaging (SMS) on Patients With Uncontrolled Hypertension · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05405478 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shiraz University of Medical Sciences
- Last refreshed: 6 June 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05405478.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing